These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 19539578

  • 1. Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands.
    Rogoza RM, Westra TA, Ferko N, Tamminga JJ, Drummond MF, Daemen T, Wilschut JC, Postma MJ.
    Vaccine; 2009 Jul 30; 27(35):4776-83. PubMed ID: 19539578
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    de Kok IM, van Ballegooijen M, Habbema JD.
    J Natl Cancer Inst; 2009 Aug 05; 101(15):1083-92. PubMed ID: 19571256
    [Abstract] [Full Text] [Related]

  • 3. The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands.
    Bogaards JA, Coupé VM, Meijer CJ, Berkhof J.
    Vaccine; 2011 Nov 08; 29(48):8929-36. PubMed ID: 21945961
    [Abstract] [Full Text] [Related]

  • 4. [Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses].
    Westra TA, Daemen T, Postma MJ, Wilschut JC.
    Ned Tijdschr Geneeskd; 2009 Nov 08; 153():A356. PubMed ID: 19930733
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of human papilloma virus vaccination in Iceland.
    Oddsson K, Johannsson J, Asgeirsdottir TL, Gudnason T.
    Acta Obstet Gynecol Scand; 2009 Nov 08; 88(12):1411-6. PubMed ID: 19900074
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account.
    Luttjeboer J, Westra TA, Wilschut JC, Nijman HW, Daemen T, Postma MJ.
    Vaccine; 2013 Aug 20; 31(37):3922-7. PubMed ID: 23806241
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia.
    Obradovic M, Mrhar A, Kos M.
    Eur J Public Health; 2010 Aug 20; 20(4):415-21. PubMed ID: 20624834
    [Abstract] [Full Text] [Related]

  • 8. Health and economic impact associated with a quadrivalent HPV vaccine in Italy.
    Mennini FS, Giorgi Rossi P, Palazzo F, Largeron N.
    Gynecol Oncol; 2009 Feb 20; 112(2):370-6. PubMed ID: 19041125
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
    Reynales-Shigematsu LM, Rodrigues ER, Lazcano-Ponce E.
    Arch Med Res; 2009 Aug 20; 40(6):503-13. PubMed ID: 19853192
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening.
    Thiry N, De Laet C, Hulstaert F, Neyt M, Huybrechts M, Cleemput I.
    Int J Technol Assess Health Care; 2009 Apr 20; 25(2):161-70. PubMed ID: 19366497
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France.
    Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V.
    Int J Technol Assess Health Care; 2008 Apr 20; 24(1):10-9. PubMed ID: 18218164
    [Abstract] [Full Text] [Related]

  • 15. Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis.
    Ginsberg GM, Edejer TT, Lauer JA, Sepulveda C.
    Vaccine; 2009 Oct 09; 27(43):6060-79. PubMed ID: 19647813
    [Abstract] [Full Text] [Related]

  • 16. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY.
    Vaccine; 2008 Jul 29; 26(32):4080-93. PubMed ID: 18550229
    [Abstract] [Full Text] [Related]

  • 17. [Vaccines against human papillomavirus (HPV); between registration and implementation].
    van Rossum TG, de Melker HE, Houweling H, Voordouw AC, Meijer CJ, Helmerhorst TJ, Kretzschmar M, Berkhof J, van der Noordaa J.
    Ned Tijdschr Geneeskd; 2008 Apr 26; 152(17):987-92. PubMed ID: 18549172
    [Abstract] [Full Text] [Related]

  • 18. The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa.
    Sinanovic E, Moodley J, Barone MA, Mall S, Cleary S, Harries J.
    Vaccine; 2009 Oct 19; 27(44):6196-202. PubMed ID: 19698807
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
    Novaes HM, de Soárez PC, Silva GA, Ayres A, Itria A, Rama CH, Sartori AM, Clark AD, Resch S.
    Vaccine; 2015 May 07; 33 Suppl 1():A135-42. PubMed ID: 25919154
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB, Mendoza LO, García O, Díaz I, Figueroa J, Duarte RM, Perdomo G, Garcia AG, Janusz CB.
    Vaccine; 2015 May 07; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.